Theravance board adds Slater
Executive Summary
Former HHS Assistant Secretary for Health Eve Slater has joined Theravance's board of directors, the firm announced Dec. 12. Before joining HHS, Slater was Merck VP-external policy & public affairs. Slater rejoins former Merck CEO and current Theravance Chairman Roy Vagelos on the board. Slater serves on the boards of a number of other firms, including Vertex and VaxGen (1"The Pink Sheet" July 18, 2005, In Brief)...
You may also be interested in...
Ex-HHS official joins VaxGen board
Eve Slater joins VaxGen board of directors. Slater served as assistant secretary for health and chief policy advisor to former HHS Secretary Tommy Thompson. Before joining HHS, she was Merck's VP-external policy & public affairs. Slater also serves on the board of data management solutions firm Phase Forward and Vertex Pharmaceuticals (1"The Pink Sheet" June 27, 2005, In Brief)...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.